A federal judge returned Bayer’s (BAYN.DE) $7.25 billion Roundup class-action settlement to Missouri state court on Wednesday, rejecting objectors’ bid to shift the case to California and prolonging the liability overhang that has erased more than half the company’s market value since its 2018 Monsanto acquisition.
The ruling keeps the settlement on track for a July 9 final-approval hearing in St. Louis but does not resolve deep constitutional objections that legal observers say could unravel the deal entirely.
Key Takeaways
- Federal judge remands $7.25B Roundup settlement to Missouri state court.
- Objectors cite due-process flaws and a burdensome opt-out process.
- Final approval hearing set for July 9; Supreme Court ruling still pending.
Market Reaction & Context
Bayer’s market capitalisation has collapsed to roughly $25 billion, down from the $63 billion it paid for Monsanto in 2018, as Roundup litigation costs have exceeded $11 billion in resolved claims alone. 1 By comparison, peers such as BASF and Corteva Agriscience have not faced equivalent product-liability drag, underscoring the singular financial weight Roundup continues to exert on Bayer’s equity story.
With approximately 61,000 to 65,000 claims still active across U.S. courts, the proposed settlement represents Bayer’s most ambitious attempt yet to cap its exposure in a single transaction. 2 The company has already secured an $8 billion loan facility to fund potential payouts, signalling the magnitude of the financial commitment.
Detailed Analysis
The procedural battle centres on a May 22 “notice of removal” filed by attorney Ashley Keller, who argued that objecting cancer plaintiffs should be treated as defendants – a novel legal theory that the federal court ultimately declined to validate by sending the case back to Missouri. 1 The transfer to the Judicial Panel on Multidistrict Litigation’s California docket, briefly ordered in early June, also complicated matters before the case was remanded.
Objectors, including 13 individuals who allege non-Hodgkin lymphoma from long-term Roundup use, contend that the settlement’s opt-out mechanism imposes 11 discrete procedural requirements, creating what one filing called an “outrageous” barrier that risks invalidating legitimate opt-outs on technicalities. 1 The deal’s structure would bind not only existing claimants but also future Roundup users who develop cancer – a class potentially spanning millions of people, including minors and individuals not yet born.
Critics have also focused on the $675 million attorney-fee request embedded in the deal, equal to 9.3% of the total fund, while average payouts for residential users diagnosed with aggressive non-Hodgkin lymphoma before age 60 are estimated at approximately $40,000. 2 More than 100 class members and a dozen healthcare plans have now filed formal objections ahead of the July hearing.
Outlook & Management Comment
Bayer said the removal notice had “no merit” and that the settlement belongs in Missouri state court, where the overwhelming majority of remaining claims have been filed. 1 The company added that objections are routine in large nationwide settlements and will be addressed at the July hearing.
“We remain confident that the long-term and well-financed proposed class settlement plan, which is supported by plaintiff law firms representing thousands of potential class members, is fair to all claimants, and warrants approval by the court,” Bayer said in a statement.
Settlement architect Chris Seeger called the removal notice “a baseless delay tactic that should be promptly denied,” arguing that the deal offers the clearest path to “guaranteed compensation for cancer victims who have waited more than a decade for justice.” 1
Supreme Court Wildcard
Hovering over the entire proceedings is a pending U.S. Supreme Court ruling in Monsanto v. Durnell, which will decide whether the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) pre-empts state-law failure-to-warn claims – the legal theory underpinning most Roundup verdicts. 2 The opt-out deadline for the proposed settlement was June 4, weeks ahead of an expected late-June ruling, a sequencing that objectors said pressured plaintiffs to forgo individual claims before knowing whether those claims had been weakened by the court.
A ruling in Monsanto’s favour could sharply reduce Bayer’s future trial exposure but would also validate concerns that plaintiffs who opted out missed their best chance at compensation. Bayer has framed both the settlement and the Supreme Court case as potential “turning points” in litigation that has dogged the company for eight years.
Conclusion
Wednesday’s remand preserves the Missouri forum that Bayer and settlement-supporting plaintiff firms prefer, but it does not silence the constitutional objections that MDL Judge Vince Chhabria – who has called the deal “filthy” and “legally problematic” – has flagged without yet acting upon. 1 For macro-focused investors, the key variables remain July 9 approval, Supreme Court timing, and whether participation rates stay high enough to prevent Bayer from exercising its walk-away right.
Not investment advice. For informational purposes only.
References
1Carey Gillam, The New Lede (May 26, 2026). “Bayer’s proposed Roundup settlement violates Constitution, new legal filing claims”. Investigate Midwest. Retrieved June 17, 2026.
2(June 2026). “Monsanto Roundup Lawsuit Update”. Lawsuit Information Center. Retrieved June 17, 2026.
3St. Louis Business Journal (May 27, 2026). “Plaintiffs seek to send $7.25B Roundup settlement back to Missouri state court”. X (formerly Twitter) / St. Louis Business Journal. Retrieved June 17, 2026.